Cyclic pyranopterin monophosphate

Drug Profile

Cyclic pyranopterin monophosphate

Alternative Names: ALXN-1101; cPMP; cPMP-cpd

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Orphatec Pharmaceuticals
  • Developer Alexion Pharmaceuticals
  • Class Organophosphorus compounds; Pterins
  • Mechanism of Action Molybdenum cofactor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Molybdenum cofactor deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Molybdenum cofactor deficiency

Most Recent Events

  • 27 Oct 2016 Alexion initiates enrolment in a phase II/III trial for Molybdenum-cofactor deficiency (In neonates) in USA, Israel, Spain, Germany and United Kingdom
  • 03 Feb 2016 Phase-II/III clinical trials in Molybdenum-cofactor deficiency (In neonates) in Germany, United Kingdom, USA (IV)
  • 24 Dec 2015 Alexion Pharmaceuticals plans a phase II/III trial for Molybdenum cofactor deficiency (In neonates) in USA, Germany and the United Kingdom (NCT02629393)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top